Latest Breaking News On - Josef penninger - Page 12 : comparemela.com
Penninger-Medikament wird auf Verabreichung mittels Inhalation getestet
kurier.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kurier.at Daily Mail and Mail on Sunday newspapers.
(Blut)-Spenden retten kranken Kindern in Wien das Leben
heute.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from heute.at Daily Mail and Mail on Sunday newspapers.
(0)
Three-target, multi-year collaboration includes the development of bispecific antibodies to treat sight-threatening complication of type 1 and 2 diabetes
AbCellera (Nasdaq: ABCL) and Angios GmbH (Angios) announced today that they have entered into a multi-year, multi-target collaboration to facilitate the discovery of monoclonal and bispecific antibodies for vascular diseases of the eye. AbCellera will use its full stack, AI-powered antibody discovery platform to generate panels of antibodies for up to three Angios-selected targets to address diabetic retinopathy. Through this collaboration, Angios can focus on advancing their unique scientific insights for treating blindness in diabetes, rather than on establishing and scaling internal antibody discovery capabilities, said Carl Hansen, Ph.D., CEO and President of AbCellera. We are excited to work closely with Angios to start their programs without delay, including identifying bispecific antibodies against diabetic retinop
Search jobs AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy
Three-target, multi-year collaboration includes the development of bispecific antibodies to treat sight-threatening complication of type 1 and 2 diabetes
VANCOUVER, British Columbia & INNSBRUCK, Austria (BUSINESS WIRE) $ABCL#antibodies AbCellera (Nasdaq: ABCL) and Angios GmbH (Angios) announced today that they have entered into a multi-year, multi-target collaboration to facilitate the discovery of monoclonal and bispecific antibodies for vascular diseases of the eye. AbCellera will use its full stack, AI-powered antibody discovery platform to generate panels of antibodies for up to three Angios-selected targets to address diabetic retinopathy.
Article content
“Lectins are proteins that can bind the sugar molecule structure on lipids or proteins such as the spike protein. Our idea is to harness this property to develop a drug to combat COVID-19 disease.”
What you see in the video, he said, is the single spike (the large bright object) and lectins (smaller fast-moving objects).
It was shot at 303 milliseconds per frame over an area of the virus measuring 100 X 100 nm² (nanometres are one-billionth of a metre), using something called atomic force microscopy at the University of Linz, Austria.
“This is what it looks like in real time when the spike binds to something,” Penninger said. “Very few people have this microscope, so it was great to hook up with people who do some really cool stuff with cool technologies.”
vimarsana © 2020. All Rights Reserved.